Signum Dermalogix Inc., a private biopharmaceutical company, has entered into a partnership with Elizabeth Arden, Inc. focusing on a semi-exclusive global license for the cosmetic functional ingredient Arazine (N-acetyl-S-farnesyl-cysteine) as well as developing new screening methodologies to measure the anti-oxidant potential of Arden’s other product ingredients. Arazine, which was initially discovered at Princeton University, possesses anti-inflammatory and anti-oxidant properties, ...